The global isothermal nucleic acid amplification technology (INAAT) market size reached USD 3.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2033, exhibiting a growth rate (CAGR) of 10.3% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 3.4 Billion |
Market Forecast in 2033
|
USD 8.2 Billion |
Market Growth Rate 2025-2033 | 10.3% |
The isothermal nucleic acid amplification technology (INAAT) is used in molecular biology and recombinant DNA technologies for detecting and identifying nucleic acids. It is commonly used to amplify nucleic acids at a constant temperature, thereby eliminating the need for thermocycler equipment. It is majorly utilized for RNA, DNA, cells, proteins, small molecules, and ions to ensure the rapid, sensitive and accurate diagnosis of genetic, inherited, and infectious diseases. It generates amplicons that are employed in producing versatile nucleic acid nanomaterials. Besides this, it assists in detecting various infectious diseases, such as (HIV), tuberculosis, influenza, hepatitis A and B, chlamydia, and gonorrhea (CT/NG). As a result, INAAT is gaining immense traction across the globe.
The ongoing development in INAAT for detecting coronavirus disease (COVID-19) represents one of the key factors positively influencing the market. In line with this, the increasing geriatric population globally and the rising prevalence of cancer and other chronic medical disorders, along with the escalating demand for efficient diagnosis and treatment alternatives, are contributing to the market growth. Apart from this, the adoption of loop-mediated isothermal amplification (LAMP) tests to amplify DNA and RNA and the identification of genetically modified organisms (GMOs) is catalyzing the demand for INAAT. Furthermore, the development of strand displacement amplification (SDA), single primer isothermal amplification (SPIA), and recombinase polymerase amplification (RPA) are acting as another growth-inducing factor. Moreover, increasing investments in research and development (R&D) activities by leading market players are projected to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global isothermal nucleic acid amplification technology market report, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on product, technology, application, and end-user.
Breakup by Product:
Reagents hold the majority of the global isothermal nucleic acid amplification technology market share due to their increasing use in therapeutics.
Breakup by Technology:
TMA accounts for the majority of the total market share as it allows a clinical laboratory to perform nucleic acid test (NAT) assays for blood screening with fewer steps and less processing time.
Breakup by Application:
Infectious disease diagnosis currently dominates the market due to the rising prevalence of infectious diseases across the globe.
Breakup by End-User:
Hospitals presently dominate the market due to the increasing number of hospitals and significant development in the healthcare industry.
Breakup by Region:
North America exhibits a clear dominance in the market due to the shifting consumer preference for INAAT testing over traditional diagnostic procedures.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Abbott Laboratories, bioMérieux SA, Becton, Dickinson and Company, Eiken Chemical Co. Ltd., Hologic Inc., Meridian Bioscience Inc., OptiGene Limited, Thermo Fisher Scientific Inc., Tecan Trading AG, and Ustar Biotechnologies Ltd.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product, Technology, Application, End-User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, bioMérieux, BD (Becton, Dickinson and Company), Eiken Chemical Co. Ltd., Hologic Inc., Meridian Bioscience Inc., OptiGene Limited, Thermo Fisher Scientific Inc., Tecan Trading AG and Ustar Biotechnologies Ltd. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |